AAUM (Average Assets Under Management) of ₹1,063.05 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 73.3% | 74.9% | ▲ +1.7% |
| Healthcare Services | 21.6% | 21.6% | ● +0.0% |
| Insurance | 0.8% | 0.7% | ● -0.1% |
| Chemicals & Petrochemicals | 0.8% | 0.7% | ● -0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 74.9% | 76.4% | ▲ +1.5% |
| Healthcare Services | 21.6% | 21.7% | ▲ +0.1% |
| Insurance | 0.7% | 0.7% | ● 0.0% |
| Chemicals & Petrochemicals | 0.7% | 0.6% | ▼ -0.1% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Weight (Oct 2026) |
|---|---|---|---|
| 1 | Eris Lifesciences Limited ₹17.35 Cr |
Pharmaceuticals & Biotechnology | 1.59% |
| 2 | Onesource Specialty Pharma Limited ₹9.38 Cr |
Pharmaceuticals & Biotechnology | 0.86% |
| # | Stock | Sector | Last Weight (Sep 2026) |
|---|---|---|---|
| 1 | Shilpa Medicare Ltd ₹15.39 Cr |
Pharmaceuticals & Biotechnology | 1.43% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Cipla Limited ₹77.28 Cr |
Pharmaceuticals & Biotechnology | 6.38% | 7.10% | +0.72% |
| 2 | Dr. Reddy's Laboratories Limited ₹20.14 Cr |
Pharmaceuticals & Biotechnology | 1.13% | 1.85% | +0.72% |
| 3 | Dr. Lal Path Labs Limited ₹42.43 Cr |
Healthcare Services | 3.51% | 3.90% | +0.39% |
| 4 | Biocon Limited ₹19.42 Cr |
Pharmaceuticals & Biotechnology | 1.45% | 1.79% | +0.34% |
| 5 | Piramal Pharma Limited ₹16.68 Cr |
Pharmaceuticals & Biotechnology | 1.22% | 1.53% | +0.31% |
| 6 | Apollo Hospitals Enterprise Limited ₹71.75 Cr |
Healthcare Services | 6.44% | 6.60% | +0.16% |
| 7 | Gland Pharma Limited ₹31.12 Cr |
Pharmaceuticals & Biotechnology | 2.70% | 2.86% | +0.16% |
| 8 | Divi's Laboratories Limited ₹25.43 Cr |
Pharmaceuticals & Biotechnology | 2.24% | 2.34% | +0.10% |
| 9 | Syngene International Limited ₹7.61 Cr |
Healthcare Services | 0.64% | 0.70% | +0.06% |
| 10 | Metropolis Healthcare Limited ₹16.73 Cr |
Healthcare Services | 1.48% | 1.54% | +0.06% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Torrent Pharmaceuticals Limited ₹96.08 Cr |
Pharmaceuticals & Biotechnology | 9.28% | 8.83% | -0.45% |
| 2 | GlaxoSmithKline Pharmaceuticals Limited ₹5.71 Cr |
Pharmaceuticals & Biotechnology | 0.83% | 0.53% | -0.30% |
| 3 | Thyrocare Technologies Limited ₹16.18 Cr |
Healthcare Services | 1.76% | 1.49% | -0.27% |
| 4 | Sun Pharmaceutical Industries Limited ₹90.81 Cr |
Pharmaceuticals & Biotechnology | 8.61% | 8.35% | -0.26% |
| 5 | Abbott India Limited ₹33.15 Cr |
Pharmaceuticals & Biotechnology | 3.26% | 3.05% | -0.21% |
| 6 | Ajanta Pharma Limited ₹45.37 Cr |
Pharmaceuticals & Biotechnology | 4.35% | 4.17% | -0.18% |
| 7 | Emcure Pharmaceuticals Limited ₹33.27 Cr |
Pharmaceuticals & Biotechnology | 3.21% | 3.06% | -0.15% |
| 8 | Suraksha Diagnostic Ltd ₹10.59 Cr |
Healthcare Services | 1.10% | 0.97% | -0.13% |
| 9 | Vinati Organics Limited ₹6.35 Cr |
Chemicals & Petrochemicals | 0.69% | 0.58% | -0.11% |
| 10 | SANOFI CONSUMER HEALTHCARE ₹10.86 Cr |
Pharmaceuticals & Biotechnology | 1.11% | 1.00% | -0.11% |
40 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹96.08 Cr |
Pharmaceuticals & Biotechnology |
8.83%
|
|
| 2 |
₹90.81 Cr |
Pharmaceuticals & Biotechnology |
8.35%
|
|
| 3 |
₹77.28 Cr |
Pharmaceuticals & Biotechnology |
7.10%
|
|
| 4 |
₹71.75 Cr |
Healthcare Services |
6.60%
|
|
| 5 |
₹49.41 Cr |
Pharmaceuticals & Biotechnology |
4.54%
|
|
| 6 |
₹48.97 Cr |
Pharmaceuticals & Biotechnology |
4.50%
|
|
| 7 |
₹45.37 Cr |
Pharmaceuticals & Biotechnology |
4.17%
|
|
| 8 |
₹42.43 Cr |
Healthcare Services |
3.90%
|
|
| 9 |
₹38.78 Cr |
Pharmaceuticals & Biotechnology |
3.56%
|
|
| 10 |
₹33.27 Cr |
Pharmaceuticals & Biotechnology |
3.06%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.